Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

The large heterogeneity in response to immune checkpoint inhibitors is driving the exploration of predictive biomarkers to identify patients who will respond to such treatment. We extended our previously suggested modeling framework of atezolizumab pharmacokinetics, IL18, and tumor size (TS) dynamic...

Full description

Saved in:
Bibliographic Details
Main Authors: Ida Netterberg (Author), René Bruno (Author), Ya‐Chi Chen (Author), Helen Winter (Author), Chi‐Chung Li (Author), Jin Y. Jin (Author), Lena E. Friberg (Author)
Format: Book
Published: Wiley, 2020-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available